Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 68, No 1 (2017)
Original paper
Submitted: 2015-08-27
Accepted: 2015-11-23
Published online: 2016-01-22
View PDF Download PDF file
Get Citation

Paraoxonase 1 polymorphisms (L55M and Q192R) as a genetic marker of diabetic nephropathy in youth with type 1 diabetes

Ons Fekih, Sonia Triki, Jihene Rejeb, Fadoua Neffati, Wahiba Douki, Asma Ommezzine, Slaheddine Chouchane, Mohamed Neji Guediche, Ali Bouslama, Mohamed Fadhel Najjar
DOI: 10.5603/EP.a2016.0027
·
Pubmed: 26884296
·
Endokrynol Pol 2017;68(1):35-41.

open access

Vol 68, No 1 (2017)
Original Paper
Submitted: 2015-08-27
Accepted: 2015-11-23
Published online: 2016-01-22

Abstract

Introduction: Paraoxonase 1 (PON1) polymorphisms have been largely involved in diabetes complications. The aim of the study is to evaluate the effects of PON1 polymorphisms (L55M and Q192R) on diabetic nephropathy (DN).

Material and methods: The study involved 116 children and adolescents with type 1 diabetes (T1D) and 91 healthy subjects. Albumin excretion rate (AER) was determined by immunoturbidimetry. PON1 activity was measured by a spectrophotometric method, and genotyping of PON1 gene was assessed by multiplex PCR followed by RFLP.

Results: PON1 activity was inversely correlated to AER (r = –0.245, p = 0.008). A significant decrease (p = 0.037) in PON1 activity was shown between patients with nephropathy and those without (162 [57–618] vs. 316 [37–788] IU/L, respectively). The distribution of AER was, for L55M polymorphism MM > LM > LL (p = 0.002), and for Q192R polymorphism QQ > QR > RR (p < 0.001). The opposite distribution was noted for PON 1 activity (p < 0.001). LMQQ and MMQQ haplotypes seem to increase AER (p = 0.004, p = 0.003, respectively) and to reduce PON1 activity (p = 0.011, p = 0.052, respectively) in youths with T1D. However, LLRR haplotype seems to have the opposite effect.

Conclusions: This study demonstrated that PON1 polymorphisms L55M and Q192R seem to be genetic markers involved in the development of DN in T1D. (Endokrynol Pol 2017; 68 (1): 35–41)

Abstract

Introduction: Paraoxonase 1 (PON1) polymorphisms have been largely involved in diabetes complications. The aim of the study is to evaluate the effects of PON1 polymorphisms (L55M and Q192R) on diabetic nephropathy (DN).

Material and methods: The study involved 116 children and adolescents with type 1 diabetes (T1D) and 91 healthy subjects. Albumin excretion rate (AER) was determined by immunoturbidimetry. PON1 activity was measured by a spectrophotometric method, and genotyping of PON1 gene was assessed by multiplex PCR followed by RFLP.

Results: PON1 activity was inversely correlated to AER (r = –0.245, p = 0.008). A significant decrease (p = 0.037) in PON1 activity was shown between patients with nephropathy and those without (162 [57–618] vs. 316 [37–788] IU/L, respectively). The distribution of AER was, for L55M polymorphism MM > LM > LL (p = 0.002), and for Q192R polymorphism QQ > QR > RR (p < 0.001). The opposite distribution was noted for PON 1 activity (p < 0.001). LMQQ and MMQQ haplotypes seem to increase AER (p = 0.004, p = 0.003, respectively) and to reduce PON1 activity (p = 0.011, p = 0.052, respectively) in youths with T1D. However, LLRR haplotype seems to have the opposite effect.

Conclusions: This study demonstrated that PON1 polymorphisms L55M and Q192R seem to be genetic markers involved in the development of DN in T1D. (Endokrynol Pol 2017; 68 (1): 35–41)

Full Text:

View PDF Download PDF file
Get Citation

Keywords

paraoxonase 1 polymorphisms; type 1 diabetes; diabetic nephropathy; paraoxonase 1 activity

About this article
Title

Paraoxonase 1 polymorphisms (L55M and Q192R) as a genetic marker of diabetic nephropathy in youth with type 1 diabetes

Journal

Endokrynologia Polska

Issue

Vol 68, No 1 (2017)

Article type

Original paper

Pages

35-41

Published online

2016-01-22

Page views

2443

Article views/downloads

1989

DOI

10.5603/EP.a2016.0027

Pubmed

26884296

Bibliographic record

Endokrynol Pol 2017;68(1):35-41.

Keywords

paraoxonase 1 polymorphisms
type 1 diabetes
diabetic nephropathy
paraoxonase 1 activity

Authors

Ons Fekih
Sonia Triki
Jihene Rejeb
Fadoua Neffati
Wahiba Douki
Asma Ommezzine
Slaheddine Chouchane
Mohamed Neji Guediche
Ali Bouslama
Mohamed Fadhel Najjar

References (45)
  1. Nowak M, Wielkoszyński T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and C-reactive protein concentration in diabetic retinopathy. Clin Exp Med. 2010; 10(3): 185–192.
    CrossRefPubMed
  2. Tabur S, Korkmaz H, Eren MA, et al. Urotensin-II level and its association with oxidative stress in early diabetic nephropathy. J Diabetes Complications. 2015; 29(1): 115–119.
    CrossRefPubMed
  3. Mackness M, Mackness B. Current Aspects of Paraoxonase-1 Research. In: Tsugikazu Komoda. The HDL Handbook: Biological functions and clinical implications. 2nd ed. Academic Press; 2014; (Chapter11) pages 273–291.
  4. Altuner D, Suzen SH, Ates I, et al. Are PON1 Q/R 192 and M/L 55 polymorphisms risk factors for diabetes complications in Turkish population? Clin Biochem. 2011; 44(5-6): 372–376.
    CrossRefPubMed
  5. Rejeb J, Omezzine A, Rebhi L, et al. Association of PON1 and PON2 polymorphisms with PON1 activity and significant coronary stenosis in a Tunisian population. Biochem Genet. 2013; 51(1-2): 76–91.
    CrossRefPubMed
  6. Fekih O, Triki S, Hellara I, et al. Is paraoxonase 1 a marker of cardiovascular risk in youth with type 1 diabetes? (Study about 109 cases). Presse Med. 2015; 44(5): e185–e190.
    CrossRefPubMed
  7. Shahmohamadnejad S, Vaisi-Raygani A, Shakiba Y, et al. Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary report. Clin Biochem. 2015; 48(1-2): 63–69.
    CrossRefPubMed
  8. Boemi M, Leviev I, Sirolla C, et al. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001; 155(1): 229–235.
    PubMed
  9. Tomás M, Latorre G, Sentí M, et al. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol. 2004; 57(6): 557–569.
    PubMed
  10. Suszyńska-Zajczyk J, Sikora M, Jakubowski H. Paraoxonase 1 deficiency and hyperhomocysteinemia alter the expression of mouse kidney proteins involved in renal disease. Mol Genet Metab. 2014; 113(3): 200–206.
    CrossRefPubMed
  11. Murata M, Maruyama T, Suzuki Y, et al. Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus. Diabet Med. 2004; 21(8): 837–844.
    CrossRefPubMed
  12. Tiwari AK, Prasad P, B K T, et al. Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with Type 2 diabetes. J Diabetes Complications. 2009; 23(2): 102–111.
    CrossRefPubMed
  13. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21:473-480.
  14. Hofer SE, Bennetts B, Chan AK, et al. Association between PON 1 polymorphisms, PON activity and diabetes complications. J Diabetes Complications. 2006; 20(5): 322–328.
    CrossRefPubMed
  15. Leviev I, Righetti A, James RW. Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med (Berl). 2001; 79(8): 457–463.
    PubMed
  16. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995; 15(11): 1812–1818.
    PubMed
  17. Boemi M, Leviev I, Sirolla C, et al. Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis. 2001; 155(1): 229–235.
    PubMed
  18. Kao YL, Donaghue K, Chan A, et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab. 1998; 83(7): 2589–2592.
    CrossRefPubMed
  19. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis. 1991; 86(2-3): 193–199.
    PubMed
  20. Araoud M. Development of an automated method for the determination of human paraoxonase1 activity. Asian Biomedicine. 2011; 5(2).
    CrossRef
  21. Motti C, Dessì M, Gnasso A, et al. A multiplex PCR-based DNA assay for the detection of paraoxonase gene cluster polymorphisms. Atherosclerosis. 2001; 158(1): 35–40.
    PubMed
  22. Krolewski AS. Genetics of diabetic nephropathy: evidence for major and minor gene effects. Kidney Int. 1999; 55(4): 1582–1596.
    CrossRefPubMed
  23. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999; 48(1): 1–9.
    PubMed
  24. Connelly PW, Zinman B, Maguire GF, et al. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J Lipid Res. 2009; 50(6): 1216–1222.
    CrossRefPubMed
  25. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008; 299(11): 1265–1276.
    CrossRefPubMed
  26. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015; 439: 5–13.
    CrossRefPubMed
  27. Tannus LR, Drummond KR, Clemente EL, et al. Brazilian Type 1 Diabetes Study Group (BrazDiab1SG). Predictors of cardiovascular autonomic neuropathy in patients with type 1 diabetes. Front Endocrinol (Lausanne). 2014; 5: 191.
    CrossRefPubMed
  28. Mackness B, Durrington PN, Boulton AJM, et al. Serum paraoxonase activity in patients with type 1 diabetes compared to healthy controls. Eur J Clin Invest. 2002; 32(4): 259–264.
    PubMed
  29. Deakin SP, James RW. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond). 2004; 107(5): 435–447.
    CrossRefPubMed
  30. Gugliucci A, Kinugasa E, Ogata H, et al. Activation of paraoxonase 1 after hemodialysis is associated with HDL remodeling and its increase in the HDL2 fraction and VLDL. Clin Chim Acta. 2014; 430: 9–14.
    CrossRefPubMed
  31. Sun Ym. [Study of SOD and PON-1 expression in type 2 diabetes mellitus nephropathy and its clinical significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010; 26(11): 1120–1121.
    PubMed
  32. Ikeda Y, Suehiro T, Inoue M, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998; 47(5): 598–602.
    PubMed
  33. Wang H, Deng H, Liu W. [The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2002; 41(3): 179–182.
    PubMed
  34. Flekac M, Skrha J, Zídková K, et al. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol Res. 2008; 57(5): 717–726.
    PubMed
  35. Sepahvand F, Rahimi-Moghaddam P, Shafiei M, et al. Frequency of paraoxonase 192/55 polymorphism in an Iranian population. J Toxicol Environ Health A. 2007; 70(13): 1125–1129.
    CrossRefPubMed
  36. Haj Mouhamed D, Ezzaher A, Mechri A, et al. Effect of cigarette smoking on paraoxonase 1 activity according to PON1 L55M and PON1 Q192R gene polymorphisms. Environ Health Prev Med. 2012; 17(4): 316–321.
    CrossRefPubMed
  37. Ergun MA, Yurtcu E, Demirci H, et al. PON1 55 and 192 gene polymorphisms in type 2 diabetes mellitus patients in a Turkish population. Biochem Genet. 2011; 49(1-2): 1–8.
    CrossRefPubMed
  38. Jenkins AJ, Klein RI, Zheng D, Hunter S, Smith K, Lyons TJ. Paraoxonase genotype (192 Gln-Arg) and serum paraoxonase-arylesterase activity: Relationship with Type 1 diabetes and nephropathy. Diabetes 2000; 49(1): A157.
  39. Kao Y, Donaghue KC, Chan A, et al. Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med. 2002; 19(3): 212–215.
    PubMed
  40. Wang J, Yang MM, Rong SS, et al. Association of paraoxonase gene polymorphisms with diabetic nephropathy and retinopathy. Mol Med Rep. 2013; 8(6): 1845–1851.
    CrossRefPubMed
  41. Altuner D, Ates I, Suzen SH, et al. The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health. 2011; 27(10): 873–878.
    CrossRefPubMed
  42. Kaman D, Ilhan N, Metin K, et al. A preliminary study of human paraoxonase and PON 1 L/M55-PON 1 Q/R 192 polymorphisms in Turkish patients with coronary artery disease. Cell Biochem Funct. 2009; 27(2): 88–92.
    CrossRefPubMed
  43. Ozkök E, Aydin M, Babalik E, et al. Combined impact of matrix metalloproteinase-3 and paraoxonase 1 55/192 gene variants on coronary artery disease in Turkish patients. Med Sci Monit. 2008; 14(10): CR536–CR542.
    PubMed
  44. Arca M, Ombres D, Montali A, et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest. 2002; 32(1): 9–15.
    PubMed
  45. Shemesh T, Whybra C, Delgado-Sanchez S, et al. Paraoxonase (PON1) gene polymorphisms in Fabry disease: correlation with renal disease. Nephron Clin Pract. 2010; 116(4): c289–c293.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl